The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 19 October 2026, authorised plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome (FCS). This medicine is intended to reduce triglyceride levels when used alongside a low-fat diet.
FCS is a rare condition characterised by abnormally high levels of fats, known as triglycerides, in the blood. This can lead to pancreatitis, which causes severe abdominal pain.
Plozasiran works by blocking the production of apolipoprotein C3, a liver protein that slows fat breakdown, thereby helping to lower triglyceride levels. The medicine is given as a 25 mg injection under the skin every three months, and patients or their caregivers can administer it after training.
Julian Beach, Executive Director, Operations, stated that this authorisation provides an additional treatment option for adults with FCS. He noted that clinical trial data indicated a substantial reduction in triglyceride levels with plozasiran when combined with a controlled diet. The MHRA will continue to monitor the safety of plozasiran.
A main study involving 75 adults with FCS supported the authorisation. Participants receiving plozasiran showed a median reduction in triglyceride levels of approximately 80% after 10 months, compared to 17% in the placebo group. The study also observed fewer episodes of acute pancreatitis in those treated with plozasiran.
Hyperglycaemia (raised blood sugar) is the most common side effect, potentially affecting over one in 10 people. Other common side effects, which may affect up to one in 10 people, include headache, nausea, and reactions at the injection site.